Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1/2 6Phase 3 4Phase 1 3Phase 2/3 2Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 1

Interventions

Exercise 439Blood Specimen Collection 333Standard of Care 321Magnetic Resonance Spectroscopy 258Radiotherapy 255Surveys and Questionnaires 245Radiosurgery 245Educational Status 230Methods 229Early Intervention, Educational 218Practice Guidelines as Topic 146Interviews as Topic 146Biopsy 145Surgical Procedures, Operative 134Drug Therapy 133Control Groups 128Acupuncture Therapy 124Therapeutics 110Cyclophosphamide 103Palliative Care 101Counseling 101Resistance Training 95Saline Solution 90Cisplatin 90Magnetic Resonance Imaging 89Radiofrequency Ablation 86Radiotherapy, Intensity-Modulated 79Colonoscopy 79Specimen Handling 78Cognitive Behavioral Therapy 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Interventional × ponatinib × Clear all
NCT01888562 2015-12-18

Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma

Washington University School of Medicine

Phase NA Withdrawn
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡